{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Not Evaluable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"ORR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Clinical responses of samalizumab were assessed using the International Myeloma Working Group Uniform Response Criteria. ORR was defined as the percentage of participants who had either stringent complete response, complete response, very good partial response, or partial response on 2 consecutive assessments made at any time before the administration of any new therapy.\n\nThe number of participants with the individual best response and ORR for each cohort is presented.","groups":[{"description":"Participants assigned to this dose cohort received a single IV dose of samalizumab 500 mg/m\\^2. Participants who tolerated the drug and demonstrated at least stable disease received up to 3 additional cycles of samalizumab at the same dose originally received at a minimum of 28-day intervals and beginning no sooner than 6 weeks after the initial dose.","id":"OG000","title":"Samalizumab 500 mg/m^2"},{"description":"Participants assigned to this dose cohort received a single IV dose of samalizumab 600 mg/m\\^2. Participants who tolerated the drug and demonstrated at least stable disease received up to 3 additional cycles of samalizumab at the same dose originally received at a minimum of 28-day intervals and beginning no sooner than 6 weeks after the initial dose.","id":"OG001","title":"Samalizumab 600 mg/m^2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants with MM who received at least 1 dose of samalizumab.","reportingStatus":"POSTED","timeFrame":"From first dose through 10 weeks after the last dose","title":"Clinical Response Of Participants With Multiple Myeloma (MM) Following Dosing With Samalizumab","type":"SECONDARY","unitOfMeasure":"Participants"}